FBS-ASaP: Fibrobronchoscopy in ASpiration Pneumonia in the Emergency Department
Launched by AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI · Jul 15, 2024
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
The FBS-ASaP trial is a study designed to explore the best way to treat patients with aspiration pneumonia in the Emergency Department. Aspiration pneumonia occurs when food, liquid, or secretions enter the lungs, causing infection. This study will compare two methods of clearing these secretions: one using a special tube called a probe and the other using a more advanced technique called videobronchoscopy, which allows doctors to see inside the airways. By collecting data from patients who undergo these procedures, researchers hope to understand which method is more effective and if there are any risks associated with either approach.
To be eligible for this study, participants must be adults diagnosed with aspiration pneumonia and require help to clear secretions or ingesta. Some key criteria include having a confirmed diagnosis through imaging tests, showing signs of respiratory distress, or needing oxygen support. If you or someone you know is interested in participating, you can expect to be part of a registry that tracks your treatment and health outcomes over the study period. This research is important as it could lead to better treatment options for patients with aspiration pneumonia in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All adult patients who access the Emergency Department with a diagnosis of aspiration pneumonia and for whom the referring physician determines the need for aspiration of secretions or ingesta. Patients must have at least one of the following criteria
- • Radiological evidence of pneumonia (Chest X-ray/CT scan/Chest ultrasound)
- • Clinical diagnosis of aspiration pneumonia
- • Presence of secretions in the upper airways
- • Respiratory distress in a dysphagic patient
- • Need for oxygen therapy or need to increase FiO2 in patients already on home oxygen therapy
- Exclusion Criteria:
- • Lack of consent
- • Age \< 18 years
- • Pregnancy
- • Hemorrhagic diathesis
- • Malignant cardiac arrhythmias (VT, AV block excluding first-degree AV block)
- • Severe airway obstruction
About Azienda Ospedaliero Universitaria Careggi
Azienda Ospedaliero-Universitaria Careggi is a leading healthcare institution in Italy, renowned for its integration of advanced clinical research and comprehensive patient care. Situated in Florence, it operates as both a hospital and a university facility, fostering a collaborative environment that bridges innovative medical research with academic excellence. The institution is committed to improving health outcomes through cutting-edge clinical trials and the development of new therapeutic strategies, supported by a multidisciplinary team of experts dedicated to advancing medical knowledge and enhancing patient well-being.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Florence, Tuscany/Italy, Italy
Florence, , Italy
Patients applied
Trial Officials
Lorenzo Pelagatti, dr
Principal Investigator
University of Florence
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported